Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain - PubMed (original) (raw)
Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain
S Sweitzer et al. Neuroscience. 2001.
Abstract
The expression of interleukin-1beta and tumor necrosis factor has previously been shown to be up-regulated in the spinal cord of several rat mononeuropathy models. This present study was undertaken to determine whether blocking the action of central interleukin-1beta and tumor necrosis factor attenuates mechanical allodynia in a gender-specific manner in a rodent L5 spinal nerve transection model of neuropathic pain, and whether this inhibition occurs via down-regulation of the central cytokine cascade or blockade of glial activation. Interleukin-1 receptor antagonist or soluble tumor necrosis factor receptor was administered intrathecally via lumbar puncture to male Holtzman rats in a preventative pain strategy, in which therapy was initiated 1h prior to surgery. Administration of soluble tumor necrosis factor receptor attenuated mechanical allodynia, while interleukin-1 receptor antagonist alone was unable to decrease allodynia. Interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor, administered to both male and female rats in a preventative pain strategy, significantly reduced mechanical allodynia in a dose-dependent manner (P<0.01). The magnitude of attenuation in allodynia was similar in both males and females. Immunohistochemistry on L5 spinal cord revealed similar astrocytic and microglial activation regardless of treatment. At days 3 and 7 post-transection, animals receiving daily interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibited significantly less interleukin-6, but not interleukin-1beta, in the L5 spinal cord compared to vehicle-treated animals. In an existing pain paradigm, in which treatment was initiated on day 7 post-transection, interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor attenuated mechanical allodynia (P<0.05) in male rats. These findings further support a role for central interleukin-1beta and tumor necrosis factor in the development and maintenance of neuropathic pain through induction of a proinflammatory cytokine cascade.
Similar articles
- The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats.
Raghavendra V, Rutkowski MD, DeLeo JA. Raghavendra V, et al. J Neurosci. 2002 Nov 15;22(22):9980-9. doi: 10.1523/JNEUROSCI.22-22-09980.2002. J Neurosci. 2002. PMID: 12427855 Free PMC article. - Propentofylline, a glial modulating agent, exhibits antiallodynic properties in a rat model of neuropathic pain.
Sweitzer SM, Schubert P, DeLeo JA. Sweitzer SM, et al. J Pharmacol Exp Ther. 2001 Jun;297(3):1210-7. J Pharmacol Exp Ther. 2001. PMID: 11356948 - Biologic control of the tumor necrosis factor and interleukin-1 signaling cascade.
Stewart RJ, Marsden PA. Stewart RJ, et al. Am J Kidney Dis. 1995 Jun;25(6):954-66. doi: 10.1016/0272-6386(95)90582-0. Am J Kidney Dis. 1995. PMID: 7771496 Review. - Soluble immunological markers of disease activity in tuberculosis.
Saltini C, Colizzi V. Saltini C, et al. Eur Respir J. 1999 Sep;14(3):485-6. doi: 10.1034/j.1399-3003.1999.14c01.x. Eur Respir J. 1999. PMID: 10543263 Review. No abstract available.
Cited by
- The role of walking exercise on axonal regrowth and neuropathic pain markers in dorsal root ganglion after sciatic nerve injury.
Cho YH, Seo TB. Cho YH, et al. J Exerc Rehabil. 2023 Dec 26;19(6):320-326. doi: 10.12965/jer.2346522.261. eCollection 2023 Dec. J Exerc Rehabil. 2023. PMID: 38188130 Free PMC article. - Immunotherapies in chronic pain through modulation of neuroimmune interactions.
Zhao J, Huh Y, Bortsov A, Diatchenko L, Ji RR. Zhao J, et al. Pharmacol Ther. 2023 Aug;248:108476. doi: 10.1016/j.pharmthera.2023.108476. Epub 2023 Jun 10. Pharmacol Ther. 2023. PMID: 37307899 Free PMC article. Review. - Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders.
Hook G, Reinheckel T, Ni J, Wu Z, Kindy M, Peters C, Hook V. Hook G, et al. Pharmacol Rev. 2022 Jul;74(3):600-629. doi: 10.1124/pharmrev.121.000527. Pharmacol Rev. 2022. PMID: 35710131 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources